drugset / Trial / NCT00004196
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
Phase 3
Completed
3000 enrolled
University of Alabama at Birmingham
National Cancer Institute (NCI) · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
RATIONALE: Interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of interferon alfa-2b in treating patients who have melanoma with early lymph node metastasis.
Timeline
- Start
- 1999-10
- Primary completion
- 2004-10
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interferon alfa-2b | Protein / enzyme biologic | — | Intravenous |